B-CELL LYMPHOMA
Clinical trials for B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Off-the-Shelf immune cells take on tough lymphoma
Disease control CompletedThis early-stage trial is testing a new treatment called ACE1831 for adults with B-cell lymphoma that has come back or not responded to at least two prior treatments. ACE1831 uses immune cells from healthy donors that are modified to target and kill cancer cells. The study aims t…
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Acepodia Biotech, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Engineered immune cells take aim at tough childhood cancers
Disease control CompletedThis early-phase trial tested whether a new type of immune cell therapy (CD22 CAR T cells) could be safely made and given to 10 children and young adults whose B-cell leukemia or lymphoma had come back or stopped responding to treatment. The therapy uses the patient's own immune …
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Kara Lynn Davis • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Engineered immune cells show promise against tough childhood cancers
Disease control CompletedThis phase 1 trial tested a new therapy called CD22-CAR T cells in 134 children and young adults (ages 1-39) with B-cell leukemia or lymphoma that had not been cured by standard treatments. The therapy involves taking a patient's own white blood cells, modifying them in a lab to …
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Engineered immune cells take on tough blood cancers in early trial
Disease control CompletedThis study tested a new treatment called CTX131 for adults with certain blood cancers (T-cell lymphoma, B-cell lymphoma, or acute myeloid leukemia) that had returned or stopped responding to standard therapy. CTX131 uses a patient's own immune cells, modified with CRISPR gene edi…
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis study tested an oral drug called LOXO-305 (pirtobrutinib) in 803 people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other non-Hodgkin lymphomas whose cancer had stopped responding to or could not tolerate standard treatments. The goal was to find the be…
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug shows promise for Tough-to-Treat blood cancers
Disease control CompletedThis early-phase trial tested a new drug called Purinostat Mesylate in 29 people with relapsed or refractory B-cell lymphomas, a type of blood cancer. The main goals were to check safety, find the right dose, and see how the drug moves through the body. Researchers hope this drug…
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New drug candidate BR101801 tested in advanced blood cancers
Disease control CompletedThis early-phase trial tested an experimental drug called BR101801 in 26 adults with advanced blood cancers like lymphoma and leukemia that had not responded to prior treatments. The main goals were to find a safe dose and check for side effects. The study is complete, but it is …
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 26, 2026 16:53 UTC